Try our Advanced Search for more refined results
Life Sciences
- 
									October 06, 2025
									Fed. Circ. Examines $41.8M Seagen Cancer Drug Patent CaseWith a $41.8 million infringement verdict against Daiichi Sankyo at stake, a Federal Circuit panel Monday grappled with whether a Seagen breast cancer treatment patent adequately described the claimed invention and would enable a skilled person to use it. 
- 
									October 06, 2025
									Supplement Co. Sold Soviet-Era Drug As Sleep Aid, Suit SaysAn addict in recovery hit Hi-Tech Pharmaceuticals Inc. with a proposed class action on Friday in Georgia federal court alleging that he bought a sleep aid sold as a dietary supplement that actually contains a dangerous, addictive sedative first developed by the Soviet Union in the 1960s. 
- 
									October 06, 2025
									Fed. Circ. Vacates J&J's $20M Loss Over Patent OwnershipThe Federal Circuit freed Johnson & Johnson subsidiary DePuy Synthes from a $20 million infringement verdict on Monday, saying the orthopedic surgeon suing it didn't own the asserted knee replacement patents. 
- 
									October 06, 2025
									Gilead Gets HIV Generic Drugs Barred From Market Until 2036Gilead Sciences Inc. said Monday it is keeping generic forms of its HIV treatment Biktarvy off of the market until 2036 following a series of settlements with competitors. 
- 
									October 06, 2025
									2 Firms To Lead Humana Investor Suit Over Post-COVID CostsGlancy Prongay & Murray LLP and The Rosen Law Firm will co-lead consolidated shareholder derivative claims against healthcare giant Humana Inc. alleging its brass made the company downplay the "pent-up demand" that pushed up patient utilization rates on the heels of the COVID-19 pandemic. 
- 
									October 06, 2025
									Neuriva 'Brain Health' Products Don't Work, Class Suit ClaimsA proposed class of buyers sued Reckitt Benckiser LLC in Illinois federal court on Monday, alleging its Neuriva line of products make promises about supporting brain health that they come nowhere near delivering. 
- 
									October 06, 2025
									Law Profs Say CareDx False Ad Verdict Should StandTwo law professors have urged the Third Circuit to grant medical testing company CareDx's request for another chance to argue why its $45 million false advertising verdict against a rival should be reinstated, saying a ruling nixing the verdict will disallow juries from using circumstantial evidence and encourage false advertisers to "try their luck." 
- 
									October 06, 2025
									3rd Circ. Rejects Novo Nordisk's Medicare Pricing ChallengeThe Third Circuit on Monday shot down another challenge to the Medicare drug price negotiation program, denying claims by pharmaceutical giant Novo Nordisk that Congress illegally delegated too much authority to the executive branch. 
- 
									October 06, 2025
									Hagens Berman Fights Sanctions Over Thalidomide SuitsPlaintiffs firm Hagens Berman Sobol Shapiro LLP strenuously denied claims that it should be sanctioned for filing since-dropped product liability cases, responding to a judge's show cause order by saying it spent hundreds of hours researching the legal theories it pursued before filing the cases and devoted substantial time and resources to them. 
- 
									October 06, 2025
									Cooley Adds Life Sciences Trio From WilmerHale, SidleyCooley LLP announced Monday that it is boosting its life sciences bench with a bicoastal trio of partners from WilmerHale and Sidley Austin LLP. 
- 
									October 06, 2025
									High Court Turns Down 6 Patent Cases At Start Of TermThe U.S. Supreme Court on Monday rejected six petitions in patent-related cases, taking some of its first actions on intellectual property matters this term. 
- 
									October 06, 2025
									Justices Won't Review Blacklisting Case Against LegitScriptThe U.S. Supreme Court refused Monday to review a bid from LegitScript to duck an antitrust case accusing it of blacklisting a drug price checking website despite contentions that it facilitates illegal imports of prescription drugs. 
- 
									October 03, 2025
									Up First At High Court: Election Laws & Conversion TherapyThe U.S. Supreme Court will hear oral arguments in six cases during the first week of its October 2025 term, including in disputes over federal candidates' ability to challenge state election laws, Colorado's ban on conversion therapy, and the ability of a landlord to sue the U.S. Postal Service for allegedly refusing to deliver mail. 
- 
									October 03, 2025
									4 Top Supreme Court Cases To Watch This TermAfter a busy summer of emergency rulings, the U.S. Supreme Court will kick off its October 2025 term Monday with only a few big-ticket cases on its docket — over presidential authorities, transgender athletes and election law — in what might be a strategically slow start to a potentially momentous term. Here, Law360 looks at four of the most important cases on the court's docket so far. 
- 
									October 03, 2025
									Few Petitions Move Forward In Newest Discretion ReviewsDeputy U.S. Patent and Trademark Office Director Coke Morgan Stewart rejected 15 Patent Trial and Appeal Board petitions Friday night, but allowed five challenges to proceed. 
- 
									October 03, 2025
									6th Circ. Will Hear Ohio PBM Fight Arguments In DecemberThe Sixth Circuit will hear arguments from the state of Ohio and the pharmacy benefit managers it's accusing of colluding to raise the price of prescription medications in December to decide whether the matter belongs in state or federal court. 
- 
									October 03, 2025
									Zynex Investors Seek To Merge, Stay Insider Trading SuitsZynex shareholders who accused company executives of inflating stock prices to cash out on shares asked a Colorado federal judge on Friday to consolidate and temporarily pause their derivative suits to wait and see how a related proposed securities class action involving significant similar facts and circumstances plays out. 
- 
									October 03, 2025
									NIH Sets Patent License Policy Aimed At Promoting AccessThe National Institutes Of Health has implemented a new policy that was proposed during the Biden administration to require those seeking commercial licenses to NIH-owned patents to detail how they will promote patient access for new drugs or medical devices they develop. 
- 
									October 03, 2025
									2nd Circ. Erases Injunction In Pet Supplement False Ad FightThe Second Circuit on Friday undid a lower court order blocking Zesty Paws from billing itself in ads as the top U.S. pet supplement brand, saying it didn't apply the proper standard correctly. 
- 
									October 03, 2025
									Benzene At NC BASF Plant Caused Cancer, Ex-Worker SaysA former worker at a North Carolina vitamin plant is suing BASF Corp. and affiliates of Takeda America Holdings Inc. in North Carolina federal court, alleging BASF exposed her to benzene, resulting in her developing cancer later in life. 
- 
									October 03, 2025
									The Roberts Court At 20: How The Chief Is Reshaping AmericaTwenty years after John Roberts became the 17th chief justice of the United States, he faces a U.S. Supreme Court term that's looking transformative for the country and its institutions. How Justice Roberts and his colleagues navigate mounting distrust in the judiciary and set the boundaries of presidential authority appear increasingly likely to define his time leading the court. 
- 
									October 03, 2025
									Stryker Gets Fed. Circ. To Ax Bone Fusion Patent ClaimsThe Federal Circuit on Friday reversed the Patent Trial and Appeal Board's findings that Stryker failed to show that certain claims were anticipated in a trio of OsteoMed patents relating to ways to secure bones together. 
- 
									October 02, 2025
									PTAB Condemns Bristol-Myers' 'Whac-A-Mole Strategy'The Patent Trial and Appeal Board has ended Amgen Inc.'s challenge to a now-disclaimed patent covering Bristol-Myers Squibb Co.'s blockbuster cancer drug Opdivo, and denied Bristol-Myers' request to pursue a replacement patent. 
- 
									October 02, 2025
									FDA OKs New Generic Abortion Pill, Drawing Conservative IreThe U.S. Food and Drug Administration has approved a second generic version of the abortion medication mifepristone, prompting outrage from anti-abortion groups and conservative politicians. 
- 
									October 02, 2025
									Feds Eye Partial Pretrial Ruling In Regeneron FCA CaseThe government has urged a Massachusetts federal judge to rule that Regeneron Pharmaceuticals "naturally or foreseeably" caused providers to present false claims for its macular degeneration drug Eylea, arguing that it does not need to prove the tougher "but-for causation" standard for its theory of false certification. 
Expert Analysis
- 
								Series Hiking Makes Me A Better Lawyer  On the trail, I have thought often about the parallels between hiking and high-stakes patent litigation, and why strategizing, preparation, perseverance and joy are important skills for success in both endeavors, says Barbara Fiacco at Foley Hoag. 
- 
								
								What US-India Trade Deal Will Mean For Indian Pharma  Complicated by newly imposed tariffs from the U.S., the outcome of the U.S.-India trade talks is poised to reshape not just trade policy, but also the strategic alignment of the two countries' pharmaceutical ecosystems, says Jashaswi Ghosh at Holon Law Partners. 
- 
								Opinion Time For Full Disclosure Of Third-Party Funding In MDLs  It is appropriate that the Federal Advisory Committee on Civil Rules is considering a rule to require disclosure of third-party litigation funding in civil litigation — something that is particularly needed in multidistrict litigation, which now comprises more than half of all civil cases in the federal courts, says Eric Hudson at Butler Snow. 
- 
								Series Law School's Missed Lessons: Negotiation Skills  I took one negotiation course in law school, but most of the techniques I rely on today I learned in practice, where I've discovered that the process is less about tricks or tactics, and more about clarity, preparation and communication, says Grant Schrantz at Haug Barron. 
- 
								
								Conflicting Developments In Homelessness Legal Landscape  Looking at an executive order and Third Circuit opinion from last month highlights the ongoing tension in homelessness-related legal issues facing state and local governments, property owners, and individuals experiencing homelessness, says Josh Collins, an attorney for the City of South Salt Lake. 
- 
								
								AG Watch: Texas Embraces The MAHA Movement.jpg)  Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks. 
- 
								Opinion Bar Exam Reform Must Expand Beyond A Single Updated Test  Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University. 
- 
								
								The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult  A survey of recent twists and turns in patent eligibility law highlights the confusion created by the U.S. Supreme Court's 2014 Alice decision and reveals that the continually shifting standards have begun to diverge in fundamental ways between the Federal Circuit and the U.S. Patent and Trademark Office, says Michael Shepherd at Fish & Richardson. 
- 
								
								Location Data And Online Tracking Trends To Watch  Regulators and class action plaintiffs are increasingly targeting companies' use of online tracking technologies and geolocation data in both privacy enforcement and litigation, so organizations should view compliance as a dynamic, cross-functional responsibility as scrutiny becomes increasingly aggressive and multifaceted, say attorneys at Arnold & Porter. 
- 
								
								A Simple Way Courts Can Help Attys Avoid AI Hallucinations  As attorneys increasingly rely on generative artificial intelligence for legal research, courts should consider expanding online quality control programs to flag potential hallucinations — permitting counsel to correct mistakes and sparing judges the burden of imposing sanctions, say attorneys at Lankler Siffert & Wohl and Connors. 
- 
								
								DOJ Consumer Branch's End Leaves FDA Litigation Questions  With the dissolution of the U.S. Department of Justice's Consumer Protection Branch set to occur by Sept. 30, companies must carefully monitor how responsibility is reallocated for civil and criminal enforcement cases related to products regulated by the U.S. Food and Drug Administration, say attorneys at Foley & Lardner. 
- 
								
								The Evolving Legal Landscape For THC-Infused Beverages  A recent Eighth Circuit ruling, holding that states may restrict the sale of intoxicating hemp-derived products without violating federal law, combined with ongoing regulatory uncertainty at both the federal and state levels, could alter the trajectory of the THC-infused beverage market, say attorneys at Pashman Stein. 
- 
								Series Creating Botanical Art Makes Me A Better Lawyer  Pressing and framing plants that I grow has shown me that pursuing an endeavor that brings you joy can lead to surprising benefits for a legal career, including mental clarity, perspective and even a bit of humility, says Douglas Selph at Morris Manning. 
- 
								Opinion The Legal Education Status Quo Is No Longer Tenable  As underscored by the fallout from California’s February bar exam, legal education and licensure are tethered to outdated systems, and the industry must implement several key reforms to remain relevant and responsive to 21st century legal needs, says Matthew Nehmer at The Colleges of Law. 
- 
								
								2nd Circ. Reinforces Consensus On Vacating Foreign Awards  In Molecular Dynamics v. Spectrum Dynamics Medical, the Second Circuit recently affirmed that federal district courts do not possess subject matter jurisdiction to vacate foreign arbitral awards, strengthening this consensus across the circuits most active in recognition and enforcement actions, says Ed Mullins at Reed Smith. 
